Market research
ALVR Allovir Inc
NASDAQ USD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 49M
- P/E ratio
- Not available
- Analyst target
- 1.2
- Dividend yield
- Not available
- Beta
- 0.62
Profile
Company facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- US0198181036
- Market cap
- 49M
- P/E ratio
- Not available
- Analyst target
- 1.2
- Dividend yield
- Not available
- Beta
- 0.62
About
About Allovir Inc
Allovir, Inc., a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus. Its preclinical and clinical development product candidates include ALVR106 for the respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; ALVR109 to treat SARS-CoV-2 and COVID-19; ALVR107 for treating hepatitis B; and ALVR108. The company was formerly known as ViraCyte, Inc. and changed its name to Allovir, Inc. in May 2019. The company was incorporated in 2013 and is based in Waltham, Massachusetts.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the ALVR discussion.
5 years, 4 months ago
AlloVir, Inc is currently in a long term downtrend where the price is trading 38.5% below its 200 day moving average.
From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.0.
Based on the above factors, AlloVir, Inc gets an overall score of 1/5.